Washington – AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, 31 May to 4 June 2024. More than 100 abstracts will feature 25 approved and potential new medicines across the Company’s diverse oncology portfolio and pipeline, including two late-breaking plenary presentations, …
London – Application is supported by data from the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival (PFS) CARTITUDE-4 is the first randomized Phase 3 study investigating the efficacy of a cell therapy as early as after first relapse in multiple myeloma RARITAN, N.J., June 6, 2023 – The Janssen Pharmaceutical Companies of Johnson …
London – AstraZeneca has announced that its daily pill decreases deaths in lung cancer patients by half. The results were talked about at the American Society of Clinical Oncology in Chicago and published in the New England Journal of Medicine. The medication, known as osimertinib and marketed as Tagrisso, targets a particular receptor that promotes the growth of cancer cells. …
